Research · PMID 39248210 · Landmark study
Reviewed by Neal Rouzier, MD, Preventive Medicine · Sep 2026
The effects and safety of testosterone replacement therapy for men with hypogonadism: the TestES evidence synthesis and economic evaluation.
Health technology assessment (Winchester, England) · August 2024 · Moira Cruickshank, Jemma Hudson, Rodolfo Hernández, Magaly Aceves-Martins, Richard Quinton, et al.
What this study found
Our findings do not support a relationship between testosterone replacement therapy and cardiovascular/cerebrovascular events in the short-to-medium term. Testosterone replacement therapy improves sexual function and quality of life without adverse effects on blood pressure, serum lipids or glycaemic markers.
Why this trial matters
TestES testosterone hypogonadism evidence synthesis
How RAGMD uses this study
Clinical questions this paper informs
Synthesis lives on the evidence question — this page shows where the study sits in that analysis.
Supporting literature
Does testosterone replacement increase cardiovascular risk?
Large randomized data (including TRAVERSE) do not show a significant increase in major adverse cardiovascular events with testosterone therapy in hypogonadal men over median follow-up of roughly three years. Older observational studies conflict, and absolute risk depends on baseline cardiovascular disease, formulation, and monitoring.
Open evidence analysisSupporting literature
Does testosterone therapy reduce cardiovascular events?
TRAVERSE found no significant difference in major adverse cardiovascular events between testosterone and placebo over trial follow-up. Meta-analyses of earlier trials are mixed; testosterone should not be prescribed primarily for cardiovascular protection.
Open evidence analysis